ps88 casino download

DALLAS (AP) — Kevin Miller had 24 points in SMU's 98-82 victory over Longwood on Sunday. Miller also added five rebounds and seven assists for the Mustangs (11-2). Yohan Traore added 20 points while going 7 of 10 from the floor, including 2 for 4 from 3-point range, and 4 for 4 from the free-throw line while and grabbed 11 rebounds. Matt Cross shot 6 for 10 (2 for 5 from 3-point range) and 5 of 6 from the free-throw line to finish with 19 points. The Mustangs prolonged their winning streak to seven games. The Lancers (11-4) were led in scoring by Elijah Tucker, who finished with 20 points and six rebounds. Longwood also got 19 points and 11 assists from Colby Garland. Emanuel Richards had 12 points. SMU took the lead as time expired in the first half on a jumper by Chuck Harris and did not give it up. Traore led their team in scoring with 15 points in the first half to help put them up 45-43 at the break. SMU pulled away with an 18-2 run in the second half to extend a nine-point lead to 25 points. They outscored Longwood by 14 points in the final half, as Miller led the way with a team-high 13 second-half points. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .Former President Jimmy Carter Dead at 100Snow plow crews to be dispatched early Tuesday night in Columbia for Wednesday snow

A high-altitude unmanned balloon once operated by Loon, formerly an Alphabet subsidiary and now registered to Raven Aerostar as "N254TH," traveled just north of the Baltimore-Washington, DC, airspace at 64,500 feet, moving east at 34 mph towards New Jersey. Data from FlightAware indicates that N254TH launched from Dangel Airport in South Dakota on Monday and has since traversed the eastern half of the US, now making its way into Delaware and soon New Jersey Zooming in... Balloon website Stratocat provided more details about the balloon under Loon's prior ownership: Project Loon was an initiative to establish a network of high altitude unmanned balloons to provide Internet connectivity in underserved parts of the world or during disaster recovery efforts. The project started in 2011 and became public in 2013 as part of Google's research and development of new technologies carried out through X Development LLC. Loon, formerly an Alphabet subsidiary, was shuttered in 2021—the project aimed to provide high-speed internet to remote parts of the world. However, Elon Musk's Starlink has largely taken over that role with its low Earth orbit satellites. Meanwhile, on X... Oh JFC... HBAL714 is registered in the US to Raven Aerostar as N254TH. It’s not a fucking Chinese balloon. pic.twitter.com/C5xyhY61ea This is not a Chinese balloon. Do some fucking research. This is a Raven Aerostar balloon registered in the US as N254TH. They’re a DoD contractor researching the uses of balloons. In addition to drones, residents of New Jersey will now have a giant balloon to speculate about.By Khari A. Thompson Injuries are part of the Kristaps Porzingis experience. The 7-foot-2 center missed Sunday’s game against the Pacers. It’s his second absence in a row, as he deals with a sprained ankle. He missed the first 17 games of this season due to offseason ankle surgery, and he has missed at least that many every season except for his first two seasons with in the league with the Knicks. But, according to Pacers coach Rick Carlisle who coached Porzingis for two seasons in Dallas, Porzingis’s injury history does not mean he lacks toughness. Carlisle reflected on Porzingis’s approach towards his rehab processes before his Pacers squad took on the Celtics at TD Garden Sunday evening. “Well, what I can tell you is that he’s a tough guy,” Carlisle said. “He’s a tough guy. He wants to play. He’s a tremendous practice player. He’s a great worker.” “When you have a [7-foot-2] body like that, it’s going to present some challenges especially with the dynamic way that he plays,” Carlisle added. “He moves around the court like a guard. But, I’ll tell you this: The guy is a competitor.” Celtics coach Joe Mazzulla said Porzingis is making strides in his recovery from his latest injury. Porzingis last played in the Celtics’ Christmas day loss to Philadelphia, during which he tweaked the ankle on an awkward step trying to drive past Joel Embiid early in the first quarter. Porzingis attempted to play through the pain, running up and down the floor with a noticeable limp. He played 13 minutes and scored nine points before his night was finished. “He’s getting better every day. He’s working at it,” Mazzulla said. “So we’ll just continue to see how he improves.” Carlisle, who was a member of the Celtics’ 1986 championship team as a player before embarking on his lengthy coaching career, said seeing Porzingis win a title with the Celtics made him happy. Porzingis’s time in Dallas did not go well. He played in just 108 of 246 possible regular-season games over the three seasons he was with the Mavericks. He averaged north of 20 points and eight per game in two of the three seasons, but he tore his meniscus in the first round of the 2020 playoffs and Dallas never made it out of the first round during his time there. He was traded to Washington during the 2022 season. Porzingis’s only full season in Washington was one of his healthiest. He played in 65 games and averaged 32.6 minutes per game. He held up for most of last season with the Celtics, before missing the vast majority of the playoffs with a calf strain followed by a torn medial retinaculum allowing dislocation of the posterior tibialis tendon. Although the ankle injury he suffered in last year’s NBA Finals eventually required offseason surgery, Porzingis made sure he was available for Game 5. Porzingis was hobbled in that game too, but the Celtics won the game and clinched their NBA-record 18th title on the TD Garden parquet floor. Carlisle said that effort was an example of Porzingis’s toughness and and character. “He’s a total team guy and whenever he has an injury he does everything in his power to get back as quickly as possible,” Carlisle said. “I was very surprised when he played in the deciding game last year. It just seemed like these guys without him were probably going to be OK anyways. But, you know, that’s just him.” “He wants to play. He wants to help his team,” he added. “He wants to be a part of the team. I know it meant an awful lot for him to win a championship, and I’m super happy for him being able to for being able to experience that here.” Khari A. Thompson Khari Thompson covers professional sports for Boston.com. Before joining the team in 2022, Khari covered college football for The Clarion Ledger in Jackson, Miss. Sign up for Celtics updates🏀 Get breaking news and analysis delivered to your inbox during basketball season. Be civil. Be kind.Holy Cross secures 82-46 victory over Regis (MA)

Uruguay's voters choose their next president in a close runoff with low stakes but much suspense MONTEVIDEO, Uruguay (AP) — Uruguayans on Sunday voted in the second round of the country's presidential election , with the conservative governing party and a left-leaning coalition locked in a close runoff following level-headed campaigns widely see Nayara Batschke, The Associated Press Nov 24, 2024 3:50 PM Share by Email Share on Facebook Share on X Share on LinkedIn Print Share via Text Message Claudia Noble stands outside the Broad Front's (Frente Amplio) election night headquarters after polls closed for the presidential run-off election in Montevideo, Uruguay, Sunday, Nov. 24, 2024. (AP Photo/Natacha Pisarenko) MONTEVIDEO, Uruguay (AP) — Uruguayans on Sunday voted in the second round of the country's presidential election , with the conservative governing party and a left-leaning coalition locked in a close runoff following level-headed campaigns widely seen as emblematic of the country's strong democracy. As polls closed Sunday evening, turnout stood at 89.4% — around the same as during the first round last month in which the two moderate coalitions both failed to win an outright majority. Voting in Uruguay is compulsory. Depending on how tight the vote turns out to be, electoral officials may not call the race for days — as happened in the contentious 2019 runoff that brought center-right President Luis Lacalle Pou to office and ended 15 years of rule by Uruguay’s left-leaning Broad Front by a razor-thin margin. Álvaro Delgado, the incumbent party’s candidate who won nearly 27% in the first round of voting on Oct. 27, has campaigned under the slogan “re-elect a good government." Other conservative parties that make up the government coalition — in particular, the Colorado Party that came in third place last month — notched 20% of the vote collectively, enough to give Delgado an edge over his challenger. Yamandú Orsi from the Broad Front, who took 44% of the vote in the general election, is promising to forge a “new left” in Uruguay that draws on the memory of stability and economic growth under his Broad Front coalition, which presided over pioneering social reforms that won widespread international acclaim from 2005-2020, including the legalization of abortion, same-sex marriage and sale of marijuana . With inflation easing and the economy expected to expand by some 3.2% this year, according to the International Monetary Fund, surveys show that Uruguayans remain largely satisfied with the administration of Lacalle Pou, who constitutionally cannot run for a second consecutive term. But persistent complaints about sluggish growth, stagnant wages and an upsurge in violent crime could just as easily add the small South American nation to a long list of places this year where frustrated voters have punished incumbents in elections around the world. With most polls showing a virtual tie between Delgado and Orsi, analysts say the vote may hinge on a small group of undecided voters — roughly 10% of registered voters in the nation of 3.4 million people. “Neither candidate convinced me and I feel that there are many in my same situation,” said Vanesa Gelezoglo, 31, in the capital, Montevideo, adding she would make up her mind at “the last minute.” Analysts say the candidates’ lackluster campaigns and broad consensus on key issues have generated extraordinary indecision and apathy in an election dominated by discussions about social spending and concerns over income inequality but largely free of the anti-establishment rage that has vaulted populist outsiders to power in neighboring Argentina and the United States. “The question of whether Frente Amplio (the Broad Front) raises taxes is not an existential question, unlike what we saw in the U.S. with Trump and Kamala framing each other as threats to democracy," said Nicolás Saldías, a Latin America and Caribbean senior analyst for the London-based Economist Intelligence Unit. “That doesn't exist in Uruguay.” Both candidates are also appealing to voter angst over the current government's struggle to stem the rise in violent crime that has shaken a nation long regarded as one of the region’s safest, with Delgado promising tough-on-crime policies and Orsi advocating a more community-oriented approach. Delgado, 55, a rural veterinarian with a long career in the National Party, served most recently as Secretary of the Presidency for Lacalle Pou and promises to pursue his predecessor’s pro-business policies. He would continue pushing for a trade deal with China that has raised hackles in Mercosur, an alliance of South American countries promoting regional commerce. "We have to give the government coalition a chance to consolidate its proposals,” said Ramiro Pérez, a street vendor voting for Delgado on Sunday. Orsi, 57, a former history teacher and two-time mayor from a working-class background, is widely seen as the political heir to former President José “Pepe” Mujica , an ex-Marxist guerilla who became a global icon for helping transform Uruguay into one of the region's most socially liberal and environmentally sustainable nations. “He's my candidate, not only for my sake but also for my children's,” Yeny Varone, a nurse at a polling station, said of Orsi. “In the future they'll have better working conditions, health and salaries.” Mujica, now 89 and recovering from esophageal cancer , turned up at his local polling station before balloting even began, praising Orsi's humility and Uruguay’s famous stability. “This is no small feat,” he said of Uruguay's “citizenry that respects formal institutions.” Orsi planned no dramatic changes, and, despite his call for a revitalized left-wing, his platform continues the Broad Front's traditional mix of market-friendly policies and welfare programs. He proposes tax incentives to lure investment and social security reforms that would lower the retirement age but fall short of a radical overhaul sought by Uruguay's unions. The contentious plebiscite on whether to boost pension payouts failed to pass in October, with Uruguayans rejecting generous pensions in favor of fiscal constraint. Both candidates pledged full cooperation with each other if elected. “I want (Orsi) to know that my idea is to form a government of national unity,” Delgado told reporters after casting his vote in the capital's upscale Pocitos neighborhood. He said that if he won, he and Orsi would chat on Monday over some yerba mate, the traditional herbal drink beloved by Uruguayans. Orsi described Sunday's democratic exercise as “an incredible experience" as he voted in Canelones, the sprawling town of beaches and cattle ranches just north of Montevideo where he served as mayor for a decade. “The essence of politics is agreements,” he said. “You never end up completely satisfied.” ___ Associated Press writer Isabel DeBre in Villa Tunari, Bolivia, contributed to this report. Nayara Batschke, The Associated Press See a typo/mistake? Have a story/tip? This has been shared 0 times 0 Shares Share by Email Share on Facebook Share on X Share on LinkedIn Print Share via Text Message More World News Jannik Sinner leads Italy past the Netherlands for its second consecutive Davis Cup title Nov 24, 2024 10:40 AM Poland's conservative opposition party taps historian as candidate for 2025 presidential run Nov 24, 2024 7:42 AM Israel says rabbi who went missing in the UAE was killed Nov 24, 2024 12:06 AM Featured FlyerWhat a difference a few percentage points can make. With just days before voters go to the polls, it feels like Sinn Féin is very much back in the game. It was all blue skies as Mary Lou McDonald gathered with her frontbench to finalise plans for the remainder of the campaign as Sinn Féin digested the latest poll results, which puts it tied with Fianna Fáil on 20% — closely behind Fine Gael on 22%. "I think the weather reflects our mood. This might be a winter election, but we have sunshine today," McDonald said. "I know talking to people, particularly over the last week, this sense of purpose now, this sense of energy has come back very, very strongly." She added that the the mood is now "very reminiscent" of the last general election, during which Sinn Féin enjoyed a surge in support. Whether Sinn Féin can repeat the outcome of the 2020 election, which saw the party return with 37 seats with many candidates topping polls and comfortably exceeding quotas, remains to be seen. However, the latest poll — coupled with Fine Gael's multiple missteps during this campaign — means Sinn Féin can no longer be ruled out, as many were doing just a few weeks ago. It could also put Fianna Fáil, which has repeatedly ruled out speaking to the opposition... Elaine Loughlin Political EditorWASHINGTON (AP) — A machinists strike. Another safety problem involving its troubled top-selling airliner. A plunging stock price. 2024 was already a dispiriting year for Boeing, the American aviation giant. But when one of the company's jets crash-landed in South Korea on Sunday, killing all but two of the 181 people on board, it brought to a close an especially unfortunate year for Boeing. Javascript is required for you to be able to read premium content. Please enable it in your browser settings. Get updates and player profiles ahead of Friday's high school games, plus a recap Saturday with stories, photos, video Frequency: Seasonal Twice a week

GEELONG, Australia, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Carbon Revolution plc (Nasdaq: CREV) (the "Company"), a Tier 1 OEM supplier and the leading global manufacturer of lightweight advanced technology automotive carbon fiber wheels, today announced that it has reached an agreement with Orion Infrastructure Capital ("OIC") for a further US$25 million financing, which will be released in five tranches, each equal to US$5 million, subject to satisfying certain release conditions. In connection with the release of each of the five tranches of US$5 million, the Company will issue to OIC and the lenders under the US$60 million PIUS loan entered into in May 2023 ("Existing Noteholders"), penny warrants to purchase an aggregate number of shares equal to 5.0% of the Company's shares outstanding. The original US$110 million funding agreement with OIC included the US$70 million previously drawn and provided for up to US$40 million of additional funding by OIC, of which this US$25 million has now been secured. In connection with this further US$25 million, Existing Noteholders have also agreed to release up to US$2 million of existing loan reserves in five equal tranches of US$400,000 concurrent with the five OIC funding tranches. Following this combined US$27 million of additional funding, both OIC and the Existing Noteholders have also agreed to partial payment in kind, in lieu of cash, for certain interest payments. The first of these five funding tranches closed on Friday December 20, 2024. The incremental $25 million of capital, reserve release and changes to interest terms, are intended to support the ongoing liquidity of the business and fund the Company as it works to satisfy the demand from Carbon Revolution's OEM customers. The Company is making substantial investments in capacity and throughput and has a number of new programs entering, or expected to enter, production in the near-term. "OIC continues to be a great funding partner for Carbon Revolution, sharing our vision for our world-leading technology," said Jake Dingle, CEO of Carbon Revolution. "This capital supports the ongoing liquidity of the business and underpins the continued delivery of our production capacity increase and the near-term launch of a number of new OEM programs." "We are firm believers in Carbon Revolution and the transformative impact of their lightweighting value proposition," said Chris Leary, Investment Partner & Head of Infra Equity at OIC. "The progress made by the Company on its capacity investments and increasing the efficiency of its production, as the only company capable of producing carbon fiber wheels at scale, has further demonstrated the unparalleled value to automotive OEMs as they modernize their product portfolios." The terms and conditions of the financing are summarized in the Company's filing with the SEC, which can be accessed here . The Company continues to work diligently to file its Annual Report as promptly as practical to regain compliance with Nasdaq Listing Rule 5250(c)(1) as described here . About Carbon Revolution plc Carbon Revolution plc (Nasdaq: CREV) (the "Company" or "Carbon Revolution") is the parent of Carbon Revolution Pty Ltd, an early-stage growth company which has successfully innovated, commercialized and industrialized the advanced manufacture of carbon fiber wheels for the global automotive industry. The Company has progressed from single prototypes to designing and manufacturing lightweight wheels for cars and SUVs in the high performance, premium and luxury segments, for the world's most prestigious automotive brands. Carbon Revolution is creating a significant and sustainable advanced technology business that supplies its lightweight wheel technology to automotive manufacturers around the world. For more information, visit carbonrev.com . Forward-Looking Statements All statements other than statements of historical facts contained in this communication are forward-looking statements. Forward-looking statements may generally be identified by the use of words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "project," "forecast," "predict," "potential," "seem," "seek," "future," "outlook," "target" or other similar expressions (or the negative versions of such words or expressions) that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the expectation of continued listing of Carbon Revolution's ordinary shares and warrants on Nasdaq, the Company's ability to file its Annual Report and promptly regain compliance with Nasdaq Listing Rule 5250(c)(1), the future financial performance, business strategies, financings and expectations for the Company's business. These statements are based on various assumptions, whether or not identified in this communication, and on the current expectations of Carbon Revolution's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from such assumptions, and such differences may be material. Many actual events and circumstances are beyond the control of Carbon Revolution. These forward-looking statements are subject to a number of risks and uncertainties, including (i) the ability to maintain the listing of Carbon Revolution's securities on Nasdaq or any other exchange on which such securities may be listed in the future; (ii) the failure to realize the benefits of being listed on a U.S. securities exchange and publicly-traded in the United States; (iii) Carbon Revolution's liquidity, including its ability to pay its obligations and to issue equity, refinance its indebtedness or otherwise obtain financing at all or on acceptable terms, (iv) risks related to its ability to meet financial covenants and other key covenants under existing financing arrangements or to obtain waivers or forbearance from compliance with such covenants, which could result in the acceleration of outstanding indebtedness, (v) changes in domestic and foreign business, market, financial, political and legal conditions; (vi) risks related to the rollout of Carbon Revolution's business strategy and the timing of expected business milestones; (vii) the effects of competition on Carbon Revolution's future business and the ability of the combined company to grow and manage growth, establish and maintain relationships with customers and retain its management and key employees; (viii) risks related to domestic and international political and macroeconomic uncertainty, including the Russia-Ukraine and conflicts in the Middle East; (ix) the outcome of any legal proceedings that may be instituted against Carbon Revolution; (x) the impact of pandemic and governmental responses on any of the foregoing risks; (xi) risks related to Carbon Revolution's industry; (xii) changes in laws and regulations; and (xiii) those factors discussed in the documents Carbon Revolution filed with the SEC, including the Shell Company Report on Form 20-F. If any of these risks materialize or Carbon Revolution's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Carbon Revolution does not presently know or that Carbon Revolution currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Carbon Revolution's expectations, plans or forecasts of future events and views as of the date of this communication. Carbon Revolution anticipates that subsequent events and developments will cause Carbon Revolution's assessments to change. However, while Carbon Revolution may elect to update these forward-looking statements at some point in the future, Carbon Revolution specifically disclaims any obligation to do so, unless required by applicable law. These forward-looking statements should not be relied upon as representing Carbon Revolution's assessments as of any date subsequent to the date of this communication. Accordingly, undue reliance should not be placed upon the forward-looking statements. For further information, please contact: Investors Investors@carbonrev.com Media Media@carbonrev.comTikTok asks court to let Trump administration review the law that would ban the appPeople comfort their children suffering from dengue fever at a government hospital in Dhaka on ... [+] October 19, 2022. (Photo by Munir uz ZAMAN / AFP) (Photo by MUNIR UZ ZAMAN/AFP via Getty Images) Dengue is a miserable illness caused by infection with any of the four dengue viruses (dengue-1, -2, -3, and -4). Infections have increased dramatically over the past two years while, at the same time, developers of anti-dengue drugs and vaccines have abandoned their research and development efforts. As a result, public health officials and clinicians are becoming increasingly concerned about their limited options to keep their populations and patients safe. The Dengue Problem is Worsening The dengue viruses primarily circulate in the tropics and subtropics and are transmitted to people by infected mosquitoes. There are an estimated 400 million infections every year making about 100 million people ill. Many recovering patients have told me dengue made them feel so sick they thought they were going to die. Annual dengue fatalities range between 8,000-40,000 people per year, with many deaths occurring in children. Once infected with a specific dengue virus, the individual will develop immunity against that virus and be protected from future illnesses for years. However, a person can always be infected a second time with a different dengue virus. It is these second infections where the risk of severe dengue and death is highest. Third or fourth infections usually do not make people very ill because of the immunity developed from the first two infections. Beginning in 2023, the global dengue problem started to significantly worsen. Dengue cases skyrocketed around the world not only in locations known to be endemic for the viruses like Central and South America and Southeast Asia, but also in new locations such as Nepal and Bangladesh. Infections this year alone are more than 300 % higher in the Caribbean and Americas compared to the average of the last five years. Cases have also started popping up in more temperate climates. France had more locally acquired dengue virus infections in 2024 than any year prior . In 2023 and 2024 the U.S. experienced an increase in the number of people becoming infected while traveling (4,730). There was also a rise in locally acquired dengue infections in places like Florida (249), Texas (2) and California (17). Puerto Rico frequently has dengue outbreaks and experienced a rise in infections with 6,452 reported cases. The Fed’s ‘Biggest Nightmare’ Is Suddenly Coming True As Bitcoin Price Surges Elon Musk Xmail Teaser Poses New Threat For Billions Of Gmail Users Mystery Drones Saga: Rand Paul Blocks Expedited Drone Bill (Updated) Where Are the Anti-Dengue Vaccines and Drugs? At the same time dengue infections are surging, vaccine and drug developers have started calling it quits in the fight against dengue. Sanofi had one of only two licensed dengue vaccines (Dengvaxia), and the only vaccine licensed in the United States. The company recently announced it will stop manufacturing Dengvaxia and existing supplies will fade away by August 2026. The company cited low global demand as the reason for discontinuing a vaccine which took over two decades and cost more than $1.5 billion dollars to develop. The other licensed dengue vaccine (TAK-003) is made by the Japanese vaccine developer Takeda. Although TAK-003 is a modest improvement over Sanofi’s vaccine, it too has significant limitations. The vaccine has a better safety profile than Dengvaxia, but it does not seem to work against the dengue-3 virus, only the dengue-1 and dengue-2 viruses. It is unclear if works against dengue-4. Millions of TAK-003 vaccine doses were provided to countries in Latin America during the recent dengue surge and observations on safety and effectiveness from real world use will be available in the coming years. The U.S. may or may not benefit from this data because the company pulled out of the Food and Drug Administration review process required for vaccine licensure. It remains to be seen whether Takeda will re-engage with the FDA and if TAK-003 will ever be available in the United States. Janssen, a company of Johnson & Johnson, has also recently thrown in the towel in the fight against dengue. The company announced that it will cease development of a drug candidate (Mosnodenvir) designed to be the first anti-viral treatment for dengue. It is unclear if another developer will license the drug and continue its development. As with Dengvaxia, Janssen’s decision represents years of lost effort and millions of dollars. (Disclosure: Throughout my career I have consulted with anti-dengue vaccine and drug developers to include Sanofi, Takeda, Janssen and Merck.) Are We Losing the Dengue War? There are plenty of reasons to be pessimistic about our ability to confront the global dengue problem and prevent its further expansion into the United States. Changing temperature and rainfall patterns have allowed the mosquito species that transmit dengue to flourish in the U.S. and extend to areas where they were not seen previously. This is a similar trend to what is being observed for diseases transmitted by ticks . A second reason for concern is that every year more than 15 million travelers enter the U.S. coming from areas where dengue viruses circulate. More than 30 million Americans travel to and return from similar areas. Every traveler has the potential to introduce a dengue virus into the country. More dengue viruses and more mosquitoes capable of transmitting them does not bode well for populations like the U.S. where most people lack immunity to any of the four dengue viruses. Air-conditioning, indoor plumbing, and window screens can limit high intensity human and mosquito interactions lowering the likelihood the U.S. will experience major dengue epidemics similar to those in Latin America and Southeast Asia. However, smaller local outbreaks like those in Key West, Florida (2009-2010) and Hawaii (2015-2016) remain possible and will stress local health care systems and cost millions of dollars to manage. Another potential bright spot is that some scientists continue to develop anti-dengue vaccine and drug candidates. There is also interest in using newer antibody infusion technologies, like what was used to treat COVID-19 patients, to prevent or treat dengue virus infections. Antibody preparations could provide short term protection from dengue during outbreaks or as a treatment for people already infected. The Serum Institute of India is field testing an antibody preparation designed to treat dengue virus infected patients. The antibodies are supposed to interrupt the virus’s multiplication in the body, thereby reducing the severity of illness patients experience. Academic groups and U.S. government agencies are also exploring the use of manufactured anti-dengue antibodies. On the vaccine front, the Instituto Butantan (Brazil) licensed dengue vaccine technology from the U.S. National Institutes of Health and have completed a large (~16,000 people) field trial testing their vaccine formulation (Butantan-DV). The vaccine appears well tolerated and prevents a significant proportion of dengue-1 and dengue-2 illnesses. The company announced it has provided Brazilian regulators (Anvisa) all the final documentation required for them make a determination on whether the vaccine can be registered and made available in Brazil. Panacea Biotech in India licensed the same NIH materials and started a large-scale vaccine field trial in 2024 . Merck (MSD) is another licensee and is also expected to launch field trials . If the vaccine is successful and MSD pursues a license in the U.S., access remains years away. What About the Future of Dengue Research? Even though academic, government, and industry groups are working on developing dengue prevention and treatment options now, there is a real risk that the resources supporting this work could soon dry up. For over a century, the U.S. government has played an important role in advancing dengue research through work in the Department of Defense , Centers for Disease Control and Prevention, and the NIH. The government has also influenced scientific advancement through its various external funding mechanisms. These activities have incentivized industry to take on the financial and scientific risk associated with developing vaccines and drug candidates where the market for the final products is unpredictable. The shared risk approach has been productive. Depending on who Congress confirms to lead the U.S. Health and Human Services and its family of subordinate agencies, infectious diseases research could be significantly de-prioritized and under resourced in both money and human capital. This would certainly limit the U.S. government’s footprint in the dengue research landscape, but also dissuade other entities from starting or continuing their dengue work. All of this would be bad news for countries like the U.S. who are almost certainly going to confront a worsening dengue problem, but currently have very few tools at their disposal to prevent or manage the infections.

These moments defined the life of Jimmy Carter

School shootings: Vallejo district’s response to potential threatsNew e-tattoos developed by University of Texas researchers can track brainwaves

OASIS, Coldplay and Dua Lipa will help drive a predicted £7billion into the UK economy next year. The British acts’ huge tours are contributing to what people in the industry are dubbing the biggest year ever for live music. Advertisement 21 Britain is set for a huge year of gigs and music tours in 2025 from stars including Dua Lipa, Coldplay and Oasis The massive appetite for tickets means concerts in the UK will help trounce the £6.1billion brought to our economy in 2023. And it is even ready to top the boost given to Britain by Taylor Swift’s Eras Tour this summer, which is now the highest-grossing tour of all time. Leading talent manager Professor Jonathan Shalit OBE, whose company Chosen Music has worked with many international artists, said: “People are embracing the live music experience more than ever before. “With the rise of social media, many younger people are spending more time online and less time together in person. Advertisement READ MORE ON MUSIC FAT CHANCE Huge Brit DJ reveals he'll NEVER release another album & has lost love for music SLADE ON THE SLIDE Rows & tragedy saw Slade go from UK's biggest band to playing tiny gigs “As a result, the demand for shared, memorable, communal experiences, such as live concerts, has never been higher. “The UK’s 2025 live music calendar is already packed with huge names such as Dua Lipa , Oasis, Katy Perry, Sabrina Carpenter, Coldplay, Gracie Abrams, Teddy Swims and Billie Eilish , all contributing to the anticipation for what will surely be a landmark year for live music. “Moreover, record companies are recognising the power of live shows to boost music sales by offering bundled concert tickets with album purchases, catering to passionate fans eager for exclusive experiences. “With so much competition in the market, artists are being forced to be more creative with their offerings and their performances, ensuring their live shows are an unforgettable experience.” Advertisement Most read in Music BLANKED SPACE Taylor Swift 'ghosted' £1,000 tartan gift from Scots council be the one Dua Lipa looks loved up with Callum Turner in first snap since engagement CHLOE SO GLOWY Chloe Bennet shows some leg in split yellow skirt at LA premiere of new show Love lessons Emmerdale’s Kelvin Fletcher opens up about family after brief split from wife Lana Del Rey, Sabrina Carpenter, Olivia Rodrigo , 50 Cent , Sam Fender and Iron Maiden have already helped drive huge revenues with their shows for 2025. R&B stars including Nelly , Sean Paul, Ashanti and Eve will also be helping to boost takings with nostalgia-driven shows. Coldplay frontman Chris Martin stops show in Sydney to save young boy in heartwarming A music industry source said: “Billions have already been generated in ticket sales, but there will be even more added from hotels, travel, food and drink. “It is becoming an increasingly lucrative market and 2025 will be the biggest year ever for live music. Advertisement “The industry is braced for a bumper year.” Billy Joel 21 Billy Joel is coming to Edinburgh and Liverpool Credit: Getty THE Piano Man will play his only Europe shows of 2025 in Edinburgh on June 7 and in Liverpool on June 21 – his first appearances in both cities for 46 years. Iron Maiden 21 Iron Maiden’s Run For Your Lives world tour includes shows in Birmingham, Manchester, London and Glasgow Credit: Getty Advertisement MARKING 50 years as a group, Iron Maiden’s Run For Your Lives world tour includes shows in Birmingham, Manchester, London and Glasgow in June. Billie Eilish 21 Billie Eilish will bring her Hit Me Hard And Soft tour to Glasgow and Dublin Credit: Getty TOURING the nation in July for the Hit Me Hard And Soft tour, beginning at Glasgow’s OVO Hydro. Her final night is at Dublin’s 3Arena on July 27. Advertisement Katy Perry 21 Katy Perry is back in Britain in October Credit: Getty SEVEN years after her last arena tour, she is back here in October for the Lifetimes Tour, hitting Glasgow, Manchester, Sheffield, Birmingham and London. Imagine Dragons 21 Imagine Dragons will bring their LOOM World Tour to London’s Tottenham Hotspur Stadium for two nights in July Credit: Getty ONE of the most popular pop-rock bands around, they will bring their LOOM World Tour to London’s Tottenham Hotspur Stadium for two nights in July, with support from Declan McKenna. Advertisement Scissor Sisters 21 The Scissor Sisters will reunite for a UK tour in May Credit: Getty CELEBRATING the 21st anniversary of their self-titled debut album, the American Take Your Mama group will reunite for a UK tour in May. Dua Lipa June 20 – 27 21 Dua Lipa is doing a stadium tour Credit: Getty Advertisement SHE sold out her Future Nostalgia arena tour last year and this time is upgrading to stadiums. Dua has two nights at London’s Wembley Stadium and will play a further two dates at Liverpool’s Anfield Stadium, plus another at Dublin’s Aviva Stadium. It follows her Glasto headline performance this summer. Coldplay Aug 22–Sep 8 Advertisement 21 Coldplay are the first band ever to sell out ten nights at Wembley Stadium in a single year Credit: Getty THEY are the first band ever to sell out ten nights at Wembley Stadium in a single year – and they follow six sold-out shows there in 2022 on the same tour. Coldplay will kick off the final swansong of their Music Of The Spheres world tour with two nights at Hull’s Craven Park, before their residency in London. The tour has grossed more than £1billion. Advertisement Olivia Rodrigo Jun 24–Jul 1 21 On top of many other shows, Olivia Rodrigo will headline her own day at BST Hyde Park in London Credit: Getty SHE only completed the Guts World Tour in October, but Olivia will now keep the party going into 2025. As well as two rescheduled shows in Manchester, she will top the bill at Dublin’s Marlay Park and is heavily rumoured to be a headliner at Glastonbury. Advertisement The singing sensation, who has had hits including Deja Vu, Vampire and Drivers License, will also headline her own day at BST Hyde Park in London. Robbie Williams May 31–Jun 14, Aug 23 21 Robbie Williams will play two nights at London’s Emirates Stadium and concerts in Manchester, Bath and Dublin in 2025 Credit: Getty ROBBIE will be embarking on a huge tour, 30 years after his departure from Take That. Advertisement Fresh from his biopic Better Man hitting cinemas, he will headline Newcastle’s inaugural Come Together Festival on June 4. Then there will be two nights at London’s Emirates Stadium and concerts in Manchester, Bath and Dublin. Sabrina Carpenter March 3 -14, Jul 5 21 Popstar Sabrina Carpenter is at the height of her fame Credit: Getty Advertisement AFTER an incredible 21 weeks at number one this year, Sabrina is ready to take the UK by storm with her Short 'N' Sweet tour. She sold out all eight arena shows in Dublin, Birmingham, London Glasgow Manchester as well as a 65,000 ticket headline concert at BST Hyde Park in July. The Espresso singer's tour which began in the states in September has received rave reviews. Lana Del Rey Jun 23-Jul 4 Advertisement 21 Lana Del Rey will play her first stadium tour here in the UK Credit: Getty THE brooding American will play her first stadium tour here in the UK. She will start in Cardiff, before shows in Glasgow, Liverpool and London, most of which has sold out. Fans will also get to hear new music from the six-time chart-topper as she will release her record, The Right Person Will Stay, in May before hitting the road. Advertisement Oasis Jul 4-Aug 17, Sep 27-28 21 The Oasis reunion announcement made headlines around the world IT is the reunion that no one thought would ever happen. Noel and Liam Gallagher have put aside their 16-year rift to kick off Oasis’s comeback at Cardiff’s Principality Stadium on July 4. Advertisement They then play shows in Manchester, London, Edinburgh and Dublin, and return to London in September for two more shows following a stint in the US. Bruce Springsteen May 14-20 and Jun 4, 7 21 Hundreds of thousands of fans are ready to turn out for three Bruce Springsteen shows Credit: Getty HE has been in music for more than 50 years and The Boss will continue to bring in the crowds. Advertisement Hundreds of thousands of fans are ready to turn out for three shows at Manchester’s Co-op Live Arena and a further two nights at Liverpool’s Anfield Stadium. Bruce will be accompanied by his E Street Band for the shows. Usher 21 Usher will play ten nights at London’s O2 Arena Credit: Getty THE American R&B superstar will play ten nights at London’s O2 Arena between March and May as part of his Past Present Future tour. Advertisement Busted v McFly 21 Busted will go head-to-head against McFly - pictured Busted's James Bourne Credit: Getty THE two Noughties pop-rock groups will go head-to-head on a 32-show tour across the UK and Ireland, kicking off in September. Kylie Minogue 21 Kylie Minogue fans will be looking forward to May Credit: Getty SIX years after her last tour, the Aussie pop princess will return to the stage for her Tension Tour, in the UK from May to early June. Advertisement ELO 21 ELO will bow out permanently in July Credit: Getty - Contributor JEFF LYNNE’s Electric Light Orchestra will bow out of music for ever in July, with gigs in Birmingham and Manchester and their final show at BST Hyde Park on July 13. Read more on the Scottish Sun GHOST TOWN Former Scots shopping hotspot 'decaying' as multimillion pound revamp ‘failing’ VAX HORROR Striken Scots 'gaslit' by health bosses after complications from Covid vaccine Olly Murs 21 Olly Murs will tour the length and breadth of the country from April to May Credit: Getty X FACTOR’s cheeky chappy will tour the length and breadth of the country from April to May before a packed schedule of summer shows from June to August. Advertisement Sam Fender 21 Sam Fender headlines London Stadium on June 6 Credit: Getty HIS album People Watching will be out in February, which gives fans plenty of time to learn it before he headlines London Stadium on June 6, and three nights at Newcastle’s St James’ Park later in the month.

When it comes to a great pair of headphones , there's no shortage out there to choose from. But the prices can vary wildly, from $25 to $250 or more. And not all of wireless earbuds offer the same features. For those with an active lifestyle, earbuds designed for sports are the antidote to the falling-out-at-every-bounce earbud, helping to keep your workout seamless. One pair, the Yamaha TW-ES5A True Wireless sports earbuds, are now available at a crazy big discount: You can grab a pair at Adorama for just $39 , down from $180. That's a wild $148 discount. But there is no telling how long this deal will last so grab a pair for someone on your gift list, and one for yourself while you're at it. With these earbuds, you get Yamaha True Sound technology for a dynamic listening experience, with a design meant to help hold your earbuds in place while moving. They are also water resistant, so you don't have to stress about sweaty workouts or sudden rain. Hey, did you know? CNET Deals texts are free, easy and save you money . Like many fitness earbuds, the Yamaha TW-ES5A True Wireless sports earbuds are not noise canceling. Instead, they allow for ambient sound, critical for making sure you are aware of your surroundings while working out in the great outdoors. Read more: Best Gifts Available on Amazon: 26 Gifts From $15 to $250 Why this deal matters A good set of earbuds is an essential, but you can easily spend a lot to get the ones you want. Normally priced at $180, the 78% discount is one of the biggest we've ever seen. It's a $141 savings, making this a low-risk, big reward deal. Will this item arrive in time for Christmas? If you’re ordering this as a holiday gift , you probably want to know if it’s going to arrive on time. With Christmas and Hanukkah both taking place on Dec. 25 this year, and Kwanzaa kicking off the day after, it’s important to note shipping deadlines for USPS, FedEx, UPS, Amazon and others . Guaranteed shipping deadlines at some of these delivery companies arrive as soon as Dec. 16, with others offering expedited services that may allow you to order as late as Dec. 23 or even Dec. 24. Where delivery is no longer possible, be sure to assess your in-store pickup options or check out these great digital deals for the holidays . The Yamaha TW-ES5A True Wireless sports earbuds will arrive in time for Christmas, according to Adorama, however be aware that you have to spend $50 in order to qualify for free two-day shipping. CNET is always covering a wide array of deals on tech products and much more. Start with the hottest sales and discounts on the CNET Deals page , and sign up for the CNET Deals Text to get daily deals sent straight to your phone. Add the free CNET Shopping extension to your browser for real-time price comparisons and cash-back offers. And peruse our gift guide , which includes a full range of ideas for birthdays, anniversaries and more.The New York Yankees have made a significant splash in the offseason, agreeing to terms with prized free agent pitcher Max Fried on a eight-year, $218 million contract, reports Jeff Passan of ESPN . Specifically, Fried, a 30-year-old left-hander, joins the Yankees after spending eight seasons with the Atlanta Braves. Building on his impressive tenure with the Braves, Fried has established himself as one of the premier pitchers in the National League. Yankees Sign Land Max Fried to Lucrative Deal One of the best pitchers to emerge from the massive rebuild the Braves undertook nearly a decade ago, Fried debuted with Atlanta in 2017. As his career progressed, he spent the next few years establishing himself as one of the game’s top starters. Most notably, he will always be remembered for the six scoreless innings he provided to clinch the 2021 World Series with a Game 6 win over the Houston Astros. Fried and the Braves agreed to a one-year, $15 million contract for the 2024 season. He was 11-10 with one shutout in 29 starts, covering 174 1/3 innings. He led the NL in ground ball percentage (58.8%) while having the second-lowest exit velocity (86.3 mph). Fried posted a .325 ERA with 7.5 hits per 9 nine innings, keeping opposing batters to a .225 batting average. This article first appeared on Last Word On Sports and was syndicated with permission.Autumn snow dumps nearly a foot in Poconos, as hunting calendar heats up